1. Introduction

Collaborative Research Liability Sharing refers to the legal principles and contractual arrangements that determine how responsibility, financial losses, legal claims, regulatory penalties, and compensation obligations are allocated among parties conducting research together.

Collaborative research may involve universities, pharmaceutical companies, biotechnology firms, hospitals, government agencies, laboratories, contract research organizations (CROs), and international research consortia.

The central legal question is:

When collaborative research causes harm, violates the law, infringes intellectual property, or produces unreliable results, which participant must bear the resulting liability?

The answer depends on the applicable jurisdiction, the parties’ respective conduct, statutory duties, the nature of the harm, and the terms of their research agreement.

For example, if a pharmaceutical company sponsors a clinical trial, a university conducts the research, and a CRO manages participant recruitment, liability for an injured participant may depend on which party controlled the relevant activity, who owed the applicable duty of care, and whether any party breached its legal obligations.

A contract can allocate financial responsibility between collaborators, but it generally cannot automatically eliminate liability to injured third parties or override mandatory statutory duties.

2. Meaning and scope

Collaborative research liability sharing has five principal dimensions:

Civil liability: Responsibility for negligence, personal injury, property damage, or economic loss.

Contractual liability: Responsibility for breaching research agreements, warranties, confidentiality obligations, or project milestones.

Regulatory liability: Responsibility for violations of research ethics, clinical-trial rules, data-protection requirements, biosafety standards, or other regulations.

Intellectual-property liability: Responsibility for patent infringement, unauthorized use of research materials, ownership disputes, and misuse of confidential information.

Financial and institutional liability: Allocation of insurance costs, compensation, litigation expenses, indemnification, and losses arising from failed or defective research.

The doctrine is not one universal statutory rule. It is a framework derived from contract law, tort law, regulatory legislation, professional duties, and judicial decisions.

3. Principal legal principles

A. Liability according to fault and control

A participant who negligently performs an assigned research task may be liable for the resulting harm. Relevant considerations include:

Who designed and approved the research protocol?

Who controlled the laboratory, equipment, or clinical procedures?

Who recruited and supervised research participants?

Who maintained safety systems and research records?

Who knew, or should have known, about the relevant risk?

Which party had the authority and practical ability to prevent the harm?

Control is an important consideration, but it is not the only one. A party may have independent statutory or professional duties even when another collaborator exercises operational control.

B. Contractual allocation of risk

Research agreements commonly allocate responsibility through indemnity clauses, insurance requirements, liability caps, warranties, and procedures for managing legal claims.

For example, a CRO may agree to indemnify a sponsor for losses caused by the CRO's negligence or material breach. The sponsor may separately accept responsibility for harm caused by its defective investigational product or failure to provide accurate safety information.

The enforceability of these provisions depends on applicable law. Courts may scrutinize exclusions for negligence, indirect losses, gross negligence, intentional misconduct, or breaches of mandatory legal duties.

C. Joint and several liability

Under some legal systems, several defendants responsible for the same indivisible harm may be liable jointly and severally. This can allow an injured person to recover the full legally recoverable amount from one liable defendant, subject to the governing rules.

The defendants may then seek contribution or indemnity from each other.

This rule does not apply identically in every jurisdiction, and contractual allocations between collaborators do not necessarily restrict an injured person's rights.

D. Independent legal duties

A collaborative research agreement does not automatically transfer every legal duty from one party to another.

A university, sponsor, investigator, manufacturer, or laboratory may retain duties imposed by statute, professional standards, ethical requirements, or its own conduct.

Consequently, an agreement stating that one collaborator assumes all liability may be ineffective against a regulator or an injured participant where the law imposes a non-delegable duty on another party.

4. Legal framework in India

For research conducted in India, liability sharing must be examined under the relevant contractual, civil, regulatory, and sector-specific laws.

A. Indian Contract Act, 1872

The principal provisions include:

Section 10: Requirements for enforceable contracts.

Section 23: Lawful consideration and object; agreements with unlawful objects are void.

Sections 124–125: Indemnity and the rights of an indemnity-holder.

Section 73: Compensation for loss or damage caused by breach of contract.

Section 74: Compensation where a contract specifies a sum payable for breach or contains a penalty stipulation, subject to the statutory rules.

An indemnity clause can allocate specified losses between collaborators. However, it does not automatically establish liability for every loss connected with the project, nor does it necessarily excuse a party from its own independent legal obligations.

B. Clinical-trial regulations

Clinical research involving human participants requires particular care because participant protection cannot be reduced to a private bargain between a sponsor and a research institution.

India's New Drugs and Clinical Trials Rules, 2019, together with applicable statutory requirements, address clinical-trial permissions, ethics committee oversight, safety reporting, medical management, and compensation for trial-related injury or death. The precise obligation depends on the applicable provisions and circumstances.

The Indian regulatory framework places significant compensation responsibilities on the sponsor in specified cases of trial-related injury or death. Contractual arrangements may allocate losses internally between the sponsor, investigator, institution, and CRO, but they should not be treated as eliminating the participant's statutory protections.

ClinRegs+1

C. Negligence and professional duties

Where research involves medical procedures, clinical judgment, laboratory safety, or the handling of biological materials, ordinary negligence principles may apply alongside the relevant regulations.

A claimant generally needs to establish the applicable duty, breach, causation, and legally recoverable damage for a negligence claim, subject to the governing cause of action.

D. Other relevant legislation

Depending on the research, relevant laws may include:

The Consumer Protection Act, 2019, where its requirements are satisfied.

The Patents Act, 1970, for patent rights and infringement.

The Information Technology Act, 2000, and applicable data-protection legislation for electronic information and personal data.

The Environment (Protection) Act, 1986, and applicable biosafety or waste-management rules.

The Bharatiya Nyaya Sanhita, 2023, where the facts satisfy the elements of a criminal offence.

The applicable legislation depends on the subject matter, the date of the conduct, and any relevant exemptions or special regulatory regimes.

5. Important case laws and their relevance

The following decisions illustrate the legal principles that shape collaborative research liability. Some directly concern research collaboration; others establish general rules relevant to indemnity, negligence, medical research, and institutional responsibility. They should not all be read as decisions specifically establishing a universal doctrine of collaborative research liability sharing.

Case 1: Gajanan Moreshwar Parelkar v. Moreshwar Madan Mantri (1942)

Bombay High Court — AIR 1942 Bom 302

Legal issue: When can a party seeking indemnity enforce its rights?

The court discussed the nature of an indemnity obligation and recognized that an indemnity-holder need not always wait until it has actually paid the entire liability before obtaining appropriate relief. The precise relief depends on the circumstances and the terms of the indemnity.

Relevance to collaborative research: Suppose a university receives a third-party claim arising from a research project and its agreement provides for indemnification by an industry sponsor. The university may need to seek appropriate protection before the claim is finally paid or adjudicated, depending on the legal position and contractual wording.

Principle: An indemnity should be drafted to address when the obligation arises, what losses it covers, and what remedies are available before and after payment.

Case 2: Osman Jamal & Sons Ltd. v. Gopal Purshottam (1928)

Calcutta High Court — AIR 1929 Cal 208

Legal issue: The rights of an indemnity-holder facing liability.

This decision is commonly cited in Indian indemnity law for the proposition that the protection afforded by an indemnity is not necessarily confined to reimbursement after the indemnity-holder has already paid the amount due.

Relevance to collaborative research: Where a research partner faces a covered claim, clear contractual provisions governing defence costs, interim payments, and settlement can be important. The decision does not mean that every research-related claim must automatically be paid by the indemnifying party.

Principle: The scope and timing of indemnity relief depend on the legal obligation and the facts of the dispute.

Case 3: Jacob Mathew v. State of Punjab (2005)

Supreme Court of India — (2005) 6 SCC 1

Legal issue: The standard for professional negligence, particularly in criminal proceedings against medical professionals.

The Supreme Court explained the distinction between civil negligence and criminal negligence and discussed the level of negligence necessary for criminal liability in medical-professional cases.

Relevance to collaborative research: Where clinicians or investigators participate in a clinical study, responsibility must be evaluated against the applicable professional standard and the actual conduct of each person. A disappointing research outcome or an adverse event does not, by itself, prove negligence or a criminal offence.

The judgment does not displace special clinical-trial compensation rules, which may impose obligations independently of proof of criminal negligence.

Principle: Liability must be determined using the appropriate legal standard, rather than inferred merely from an adverse result.

Case 4: Indian Medical Association v. V.P. Shantha (1995)

Supreme Court of India — (1995) 6 SCC 651

Legal issue: The applicability of consumer-protection law to medical services.

The Supreme Court examined when medical services fall within the scope of consumer-protection legislation, including the significance of consideration and the statutory treatment of services provided free of charge or under mixed arrangements.

Relevance to collaborative research: A research collaboration involving hospital treatment, clinical services, or participant-facing medical care may raise questions about consumer remedies as well as contractual or regulatory remedies. Whether consumer law applies depends on the actual service and statutory requirements; research participation does not automatically make every dispute a consumer dispute.

Principle: The legal character of the service and the circumstances in which it is provided matter when determining the available remedy.

Case 5: Purdue Research Foundation v. Sanofi-Synthelabo, S.A. (2003)

United States Court of Appeals for the Seventh Circuit — 338 F.3d 773 (7th Cir. 2003)

Legal issue: Enforcement of obligations arising from a sponsored research agreement.

Purdue Research Foundation and Sterling Drug had entered into an agreement involving collaborative antiviral research. The agreement included shared research funding, reporting obligations, and an indemnity relating to liabilities arising from specified commercial activities. The dispute involved contractual obligations and the consequences of a corporate transaction affecting the agreement.

media.ca7.uscourts.gov+1

Relevance to collaborative research: The case illustrates why research agreements must address more than research expenses. They should specify what happens to contractual rights and obligations when a company is acquired, a business is transferred, or research activities are continued by a successor entity.

Principle: The allocation of research costs and risks must be interpreted through the actual contractual terms and applicable law. The case should not be read as establishing automatic liability for all parties participating in a research project.

Case 6: Swasthya Adhikar Manch v. Union of India

Supreme Court of India — clinical-trial oversight litigation

This litigation concerned the regulation and ethical oversight of clinical trials in India, including safeguards for research participants.

Relevance to collaborative research: Clinical-trial responsibility cannot be understood exclusively through private contracts. Regulatory oversight, informed consent, safety monitoring, and legally required compensation remain important independent considerations.

Principle: Research collaboration must operate within the applicable public-law and regulatory framework. A contract between a sponsor and an institution cannot, by itself, displace statutory oversight.

Research note: For formal legal submissions, verify the precise order, date, and paragraph numbers of the particular proceeding being cited, because this litigation involved multiple orders.

6. Comparative summary of the case law

The first two decisions are particularly relevant to indemnity under Indian law. The American decision is persuasive only to the extent permitted by the applicable Indian legal framework.

7. Major types of liability-sharing arrangements

1. Fault-based allocation

Each collaborator bears losses attributable to its negligence, misconduct, breach of contract, or other legally attributable acts. Where several parties contribute to the same harm, applicable joint-liability and contribution rules must also be considered.

2. Indemnification

One party agrees to reimburse or protect another against specified losses, claims, liabilities, or legal expenses. The agreement should identify covered claims, exclusions, defence procedures, and settlement rights.

3. Insurance-based allocation

Parties maintain appropriate insurance, such as clinical-trial participant coverage, professional indemnity, product liability, or general liability insurance. Policy exclusions, limits, deductibles, and claims-made conditions must be reviewed.

4. Proportionate loss sharing

Collaborators agree to divide specified losses by agreed percentages, funding shares, or responsibility for particular tasks. Such an arrangement governs the parties' relationship only to the extent permitted by applicable law.

8. Drafting an effective liability-sharing clause

A collaborative research agreement should address the following matters.

The University of Texas System's sponsored-research indemnification guidance and the Canadian Medical Protective Association's clinical-research contract guidance both emphasize the importance of defining the scope of indemnity and tying responsibility to the parties' respective obligations and conduct.

The University of Texas System+1

Illustrative clause

The following is an educational drafting example, not a jurisdiction-ready contract.

Allocation of Liability and Indemnification

Each party shall be responsible, to the extent provided by applicable law and this Agreement, for losses arising from its own negligence, wilful misconduct, material breach of this Agreement, or violation of applicable law, including the acts and omissions of persons for whom it is legally responsible.

Each party shall indemnify the other party against third-party claims to the extent such claims arise from the indemnifying party's covered acts or omissions. Any indemnification obligation shall be subject to applicable insurance coverage, the agreed claims-management procedures, and the exclusions expressly stated in this Agreement.

Nothing in this clause shall exclude or restrict any participant's statutory rights, waive a mandatory regulatory obligation, or relieve a party of liability that cannot lawfully be excluded or transferred.

The parties shall promptly notify each other of material claims, cooperate in their defence, and obtain any required consent before entering into a settlement that imposes an obligation on, or admits liability on behalf of, another party.

In an actual agreement, this clause should be supplemented with specific provisions on clinical-trial injury, product liability, defence costs, mixed-fault situations, financial limits, and the relationship between indemnity and insurance.

9. Practical example: Collaborative pharmaceutical research

Consider a project involving three parties:

Company A: Sponsors the trial and supplies the investigational drug.

University B: Conducts the clinical study and supervises investigators.

CRO C: Manages recruitment, monitoring, and trial documentation.

Suppose a participant suffers an injury after a protocol deviation and a delayed safety report.

How responsibility may be assessed

Company A

Sponsor responsibilities

Examine the drug's safety profile, quality, supplied instructions, sponsor-controlled protocol decisions, and applicable participant-compensation duties.

University B

Institutional responsibilities

Examine investigator supervision, informed consent, compliance with the approved protocol, clinical care, and the institution's own statutory or professional duties.

CRO C

Operational responsibilities

Examine recruitment procedures, monitoring failures, documentation, escalation of safety signals, and compliance with delegated responsibilities.

The outcome depends on the facts and applicable law. If the CRO caused the delay, the CRO may bear contractual or tort liability where the legal elements are satisfied. If the sponsor independently failed to discharge a non-transferable obligation, outsourcing the work may not relieve the sponsor of that responsibility.

For an Indian clinical trial, the participant's compensation rights must be assessed separately under the applicable clinical-trial rules. Internal indemnity disputes should not be confused with the participant's entitlement to any legally required compensation.

ClinRegs+1

10. Defences and limitations

A collaborator may resist a claim or indemnity demand on grounds such as:

No applicable contractual obligation or duty was established.

The alleged loss was not caused by the party's conduct.

The claim falls outside the defined scope of indemnity.

The loss falls within a valid contractual exclusion or limitation.

The claimant failed to satisfy applicable procedural or notice requirements, where that failure has the relevant legal effect.

The claim is barred or restricted by applicable limitation rules.

The asserted liability or contractual restriction is inconsistent with mandatory law.

These arguments are not automatic defences. Their success depends on the wording of the agreement, the nature of the claim, the evidence, and the applicable law.

11. Governance and accountability

Effective liability sharing requires more than a well-written indemnity clause. Collaborative projects should also maintain:

A written allocation of scientific and operational responsibilities.

Documented approvals and changes to research protocols.

Regular safety and compliance reviews.

Clear procedures for reporting adverse events and research misconduct.

Traceable records of decisions, samples, data, and experimental procedures.

Independent ethics oversight where required.

Adequate insurance and a process for evaluating coverage.

A defined procedure for investigating incidents and preserving evidence.

For multicentre research in the United States, FDA guidance on cooperative research explains that institutions may use joint review arrangements, but their respective oversight responsibilities should be documented; local investigators and institutions retain responsibilities for research conducted at their sites.

FDA

12. Conclusion

Collaborative Research Liability Sharing is best understood as a combination of contractual risk allocation, indemnification, insurance, tort principles, and mandatory regulatory duties.

The principal lessons are:

Liability should be assessed against each party's actual conduct, control, and legal obligations.

Indemnity provisions should clearly define covered losses, exclusions, claims procedures, and remedies.

A contract cannot automatically extinguish the rights of injured participants or override mandatory statutory duties.

Indian indemnity decisions, including Gajanan Moreshwar Parelkar, help explain when contractual protection may be enforceable.

Clinical research requires separate attention to participant compensation, informed consent, ethics oversight, and regulatory compliance.

Overall legal principle: Effective liability sharing distributes financial responsibility among collaborators without undermining the legal rights of third parties or the independent duties imposed on each research participant by law.

Scope note: This is a general educational analysis with an India-oriented framework and selected comparative authorities. A definitive legal opinion requires the relevant agreement, the type of research, the jurisdiction, and the specific facts of the alleged loss.